<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00114452</url>
  </required_header>
  <id_info>
    <org_study_id>401</org_study_id>
    <nct_id>NCT00114452</nct_id>
  </id_info>
  <brief_title>Safety Study of Adult Mesenchymal Stem Cells (MSC) to Treat Acute Myocardial Infarction</brief_title>
  <official_title>A Phase 1 Randomized, Double-blind, Placebo-controlled, Dose Escalation, Multicenter Study to Determine the Safety of Intravenous Ex-vivo Cultured Adult Human Mesenchymal Stem Cells (Provacel) Following Acute Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mesoblast International Sàrl</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mesoblast, Ltd.</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether adult stem cells [Provacel™(PUMP1)] are safe
      and possibly effective in the treatment of acute myocardial infarction (heart attack).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiovascular disease is the single largest killer of males and females in the United States
      with an average of 335,000 deaths per year. This year an estimated 700,000 Americans will
      suffer an acute myocardial infarction. The standard of care treatment for acute myocardial
      infarction (MI) usually includes immediate perfusion, optimal pain relief, oxygen, aspirin or
      other anti-coagulants, Beta-Blockers, nitrates and Ace-inhibitors. Management of cardiac risk
      factors such as tobacco use, hypertension, lipid levels, diabetes, weight control and
      exercise all work to reduce further atherosclerotic events. Yet, many patients go on to
      develop Congestive Heart Failure (CHF). Medical management for CHF may improve symptoms and
      slow the progression to failure but does not restore a functioning myocardium. A therapy that
      could improve the myocardial remodeling process and reduce the incidence or severity of CHF
      following acute MI would provide a significant benefit in an area of unmet medical need.

      Patients will receive standard of care in addition to stem cells or placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of treatment adverse event rates between the 0.5, 1.6 and 5.0 million mesenchymal stem cells per kilogram dose cohorts and placebo groups.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Provacel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ex vivo cultured adult mesenchymal stem cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Provacel</intervention_name>
    <arm_group_label>Provacel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female between 21 and 85 years old

          -  First heart attack within 1 to 10 days

        Exclusion Criteria:

          -  Positive for HIV 1 and 2

          -  Previous heart attack

          -  Pacemaker or other device

          -  Pregnant or breastfeeding

          -  Allergic to cow or pig derived products

          -  Previous bone marrow transplant

          -  Involved in another clinical trial within the past 30 days

          -  Alcohol or recreational drug abuse within the past 6 months

          -  Hepatitis Positive

          -  Major surgical procedure or major trauma within the past 14 days

          -  Body weight greater than 300 pounds

          -  Autoimmune disease ( e.g. Lupus, Multiple Sclerosis)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joshua Hare, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Heart Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California - San Diego; Thornton</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103-8411</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Care Group</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Adventist</name>
      <address>
        <city>Takoma Park</city>
        <state>Maryland</state>
        <zip>20912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester - Strong Memorial</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Heart Institute</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Medical School</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.americanheart.org</url>
    <description>Click here for more information about heart disease</description>
  </link>
  <link>
    <url>http://www.osiris.com</url>
    <description>Click here for more information about this study and adult mesenchymal stem cells.</description>
  </link>
  <reference>
    <citation>Orlic D, Hill JM, Arai AE. Stem cells for myocardial regeneration. Circ Res. 2002 Dec 13;91(12):1092-102. Review.</citation>
    <PMID>12480809</PMID>
  </reference>
  <reference>
    <citation>Pittenger MF, Martin BJ. Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res. 2004 Jul 9;95(1):9-20. Review.</citation>
    <PMID>15242981</PMID>
  </reference>
  <reference>
    <citation>Shake JG, Gruber PJ, Baumgartner WA, Senechal G, Meyers J, Redmond JM, Pittenger MF, Martin BJ. Mesenchymal stem cell implantation in a swine myocardial infarct model: engraftment and functional effects. Ann Thorac Surg. 2002 Jun;73(6):1919-25; discussion 1926.</citation>
    <PMID>12078791</PMID>
  </reference>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2005</study_first_submitted>
  <study_first_submitted_qc>June 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2005</study_first_posted>
  <last_update_submitted>December 2, 2014</last_update_submitted>
  <last_update_submitted_qc>December 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Myocardial Infarction</keyword>
  <keyword>Heart Attack</keyword>
  <keyword>Cardiovascular Disease</keyword>
  <keyword>Stem cells</keyword>
  <keyword>Congestive Heart Failure</keyword>
  <keyword>Heart Attack Repair</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

